// App-Quantinova.ai

: Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

Researchers

Presenter

  • Nancy L. Bartlett

Principal Investigators

  • Matthew J. Matasar

  • Stephen J. Schuster

  • Sarit Assouline

  • Pratyush Giri

  • John Kuruvilla

  • Miguel Canales

  • Sascha Dietrich

  • Keith Fay

  • Matthew Ku

  • Loretta J. Nastoupil

  • Michael C. Wei

  • Shen Yin

  • Iris To

  • Huang Huang

  • Juliana Min

  • Elicia Penuel

  • L. Elizabeth Budde

Medical Centers

  • Universitat Heidelberg, Heidelberg, Germany

  • Royal Adelaide Hospital, Adelaide, Australia

  • City of Hope, Duarte, CA

  • St Vincent's Hospital, University of Melbourne, Melbourne, Australia

  • St Vincent's Hospital and Royal North Shore Hospital, Sydney, Australia

  • BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, Canada

  • MD ANDERSON CANCER CENTER, HOUSTON, TX

  • Jewish General Hospital, McGill University, Montreal, Canada

  • Princess Margaret Cancer Centre, Toronto, Canada

  • Siteman Cancer Center, Washington University School of Medicine, St Louis, MO

  • Hospital Universitario La Paz, Madrid, Spain

  • Memorial Sloan Kettering Cancer Center, New York, NY

  • Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

Locations

  • Germany

  • Spain

  • Canada

  • Australia

  • United Kingdom

  • United States

Companies

  • Feng Chi Biotech Cor

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Autoimmune (AI)

Disease

  • Cytokine release syndrome

  • Follicular lymphoma

  • Lymphomas

Biomarkers

  • Twist-related protein 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • pivotal

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved